MENU
MDGL
AS OF
Feb 3 closing price
Price
$482.45
Change
+$54.15 (+12.64%)
Capitalization
10.96B
28 days until earnings call
Intraday BUY SELL Signals
+Compare
MDGL
Stock ticker: NASDAQ
AS OF
Feb 3 closing price
Price
$482.45
Change
+$54.15 (+12.64%)
Capitalization
10.96B

MDGL Madrigal Pharmaceuticals Forecast, Technical & Fundamental Analysis

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality... Show more

MDGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MDGL with price predictions
Feb 02, 2026

MDGL in +4.15% Uptrend, growing for three consecutive days on January 27, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MDGL advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MDGL's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where MDGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDGL as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MDGL turned negative on December 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

MDGL moved below its 50-day moving average on January 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MDGL crossed bearishly below the 50-day moving average on January 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MDGL entered a downward trend on February 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.513) is normal, around the industry mean (27.778). P/E Ratio (0.000) is within average values for comparable stocks, (51.342). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.892). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (14.451) is also within normal values, averaging (333.006).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MDGL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

MDGL is expected to report earnings to fall 88.11% to -60 cents per share on March 04

Madrigal Pharmaceuticals MDGL Stock Earnings Reports
Q4'25
Est.
$-0.60
Q3'25
Missed
by $3.11
Q2'25
Beat
by $1.73
Q1'25
Beat
by $0.54
Q4'24
Beat
by $1.77
The last earnings report on November 04 showed earnings per share of -507 cents, missing the estimate of -197 cents. With 339.93K shares outstanding, the current market capitalization sits at 10.96B.
A.I. Advisor
published General Information

General Information

a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
200 Barr Harbor Drive
Phone
+1 267 824-2827
Employees
276
Web
http://www.madrigalpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
INCM29.100.14
+0.48%
Franklin Income Focus ETF
SRHR54.25N/A
N/A
SRH REIT Covered Call ETF
PEJ60.40-0.54
-0.89%
Invesco Dynamic Leisure and Entmnt ETF
CLCG26.14-0.51
-1.91%
Crossmark Large Cap Growth ETF
MFSG27.65-0.54
-1.92%
MFS Active Growth ETF

MDGL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.09%
ALXO - MDGL
56%
Loosely correlated
-3.45%
IPHA - MDGL
44%
Loosely correlated
-0.55%
GHRS - MDGL
43%
Loosely correlated
+1.02%
LCTX - MDGL
43%
Loosely correlated
+4.05%
CVM - MDGL
43%
Loosely correlated
-6.90%
More